Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

BACKGROUND: Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of icatibant is not documented in the...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Transl Allergy
Main Authors: Caballero, Teresa, Zanichelli, Andrea, Aberer, Werner, Maurer, Marcus, Longhurst, Hilary J., Bouillet, Laurence, Andresen, Irmgard
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2018
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5870812/
https://ncbi.nlm.nih.gov/pubmed/29599966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-018-0195-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares